Feasibility of Remote Evaluation and Monitoring of Acoustic Pathophysiological Signals With External Sensor Technology

Respiratory Disease Clinical Trial

— REMAP-WEST-FEA  

Official title:

A Small-scale Study to Capture Acoustic Pathophysiological Parameters, in the Community, Through a Wearable Device, and to Evaluate the Technical and Practical Feasibility of Utilising This Data as Part of a Medical Device System.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04693091
• Other study ID #: Senti-REMAP-WEST-FEA-1
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 2021
• Est. completion date: April 2021

Study information

• Verified date: December 2020
• Source: Senti Tech Ltd
• Contact: Philip Alton, Mb ChB
• Phone: +447724129546
• Email: phil.alton[@]senti.care
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to explore the acceptability and feasibility of a novel medical device system for remote monitoring of breath and heart sounds (replicating remotely, and in an easy-to-use garment, that which a clinician would do with their stethoscope to listen to a patient's chest, by evaluating sounds captured through a wearable device (Senti)). As a first-in-man study, the investigators will investigate the safety of the Senti device, the usability and acceptability of the device; and ensure technical and practical feasibility of the device in a real-world clinical setting.

10 patients will be recruited (the study participants) in two tranches (6 and 4) who are being discharged from A&E into the care of the community respiratory team. These patients will wear the Senti device. The first tranche will use the device over a single session lasting 20 minutes only. The second tranche (which will include patients from tranche one, and which will only proceed if no adverse events are detected in tranche one), participants will wear the device at their discretion (particularly encouraged to wear overnight) over the course of 5 days. The investigators will survey the study participants to answer three key questions:

1. What is the feasibility of the Senti data-capture device?

2. Is this device usable in clinical practice?

3. What are the requirements to train patients to use the device?

The investigators will also consider:

4. Does the device function technically and practically, in real-world clinical scenarios?

5. What are the key expected and unexpected safety issues related to using the device (with a particular emphasis on whether the device is likely to cause pressure sores).

These questions will establish the feasibility of using the Senti data capture device as part of a novel medical device system for the autonomous evaluation and monitoring of bioacoustic signals.

Description:

TITLE: Remote Evaluation and Monitoring of Acoustic Pathophysiological parameters with external sensor technology.

DESIGN: First-In-Man and Feasibility study of the Senti Version 1 Device.

AIMS: To explore the acceptability and feasibility of a novel medical device for the remote monitoring and evaluation of acoustic pathophysiological parameters. - To investigate usability and acceptability of the Senti data capture device, and to ensure technical and practical functionality of the device in a real-world clinical scenario.

PRIMARY OUTCOMES: Device feasibility SECONDARY OUTCOMES: Length of time with the device in situ. The ease with which patients can apply the device.

POPULATION ELIGIBILITY: Patients being discharged home with community respiratory team support, after attending A&E.

DURATION: 3 Months. (Recruitment period: 2 months. Analysis and reporting: 1 month).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: April 2021
• Est. primary completion date: March 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients attending A&E who are being discharged from A&E into the care of the community respiratory team.

Exclusion Criteria:

• Patients unable to give their consent.

• Patients with a known sensitivity or allergy to any of the components of the device.

• Patients with any active implanted devices (such as pacemakers or vagal nerve stimulators).

• Patients with existing pressure sores across the area this device would come into contact (predominantly, across the thorax).

• Patients with significant cognitive impairment or limiting physical disabilities - to the extent that they are not able to manage their own ADLs; except where sufficient family or care support is available to manage the device functions (in which case, the device may be used with caution).

Related Conditions & MeSH terms

• Respiration Disorders
• Respiratory Disease
• Respiratory Tract Diseases

Intervention

Device:
• Senti V1.0 Device
This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR. The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone.

Locations

Country	Name	City	State
United Kingdom	Senti Tech	Liverpool	Merseyside

Sponsors (1)

Lead Sponsor	Collaborator
Senti Tech Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient-rated device acceptability	Patient questionnaire "on a scale of 1 ("I would not approve at all") to 5 ("I would greatly approve and would like this to become standard practice"), to what extent would you approve of this device being used to enable clinicians to assess your heart and lung sounds as part of a telephone consultation?"	1 month
Primary	Patient-rated device comfort	Patient questionnaire "on a scale of 1 ("Very difficult to use") to 5 ("Very easy to use"), how easy to use is the device?"	1 month
Primary	Patient-rated device ease of use	Patient questionnaire "on a scale of 1 ("Too uncomfortable to use for more than an hours or so") to 5 ("As comfortable as a T-Shirt"), how comfortable is the device?"	1 month
Primary	Expert-rated device data quality	An appropriately qualified person (with clinical experience of auscultation) to rate quality of data captured by the device, as compared subjectively against the quality that they typically expect from standard auscultation, on a scale of 1 ("Much poorer data quality [than standard auscultation]") to 3 ("equivocal data quality") to 5 ("Much higher data quality").	1 month
Primary	Adverse events and adverse device events.	The number of participants experiencing adverse events, both arising from use of the device or otherwise, will be reported. Adverse events will be categorised as unexpected or expected, serious or otherwise, device-related or un-related.	1 month
Secondary	Length of time spent with the device on the patient.	Length of time over which a patient has used the device, as measured using a structured, binned multiple-choice survey. This is a custom-made scale titled "In the past 24 hours, for how many hours have you worn the Senti device?" with a minimum value of 0 hours and a maximum value of 24 hours. 8 options which include a range of times are available for selection.	1 month
Secondary	Length of time taken for the patient to apply the device	Length of time taken for the patient to put the device on, as measured by an investigator with a stop watch.	1 month
Secondary	Time spent to train patients to use the device.	Length of time taken to train patients to use the device, as measured by an investigator with a stop watch.	1 month
Secondary	Pressure sore EPUAP grade	For those patients who develop pressure sores, the pressure sore will be graded using the European Pressure Ulcer Advisory Panel grading system from a grade of grade 1 through to grade 4, including unclassified gradings and moisture lesions. (Patients will be graded as "No pressure sores" if there are no pressure sores noted on examination).	Through study completion, once per day.